English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/124600
Título

Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation

AutorBárcena, Cristina; Stefanovic, Milica ; Tutusaus, Anna; Menendez, Anghara ; García-Ruiz, Carmen ; Marí, Montserrat ; Fernández-Checa, José C. ; García de Frutos, Pablo ; Morales, Albert
Palabras claveChronic liver patients
Experimental fibrosis
Gas6/Axl serum levels
HSC activation
TAM receptors
Fecha de publicación1-sep-2015
EditorEuropean Association for the Study of the Liver
Elsevier
CitaciónJournal of Hepatology 63(3): 670-678 (2015)
Resumen© 2015 European Association for the Study of the Liver. Background & Aims Liver fibrosis, an important health concern associated to chronic liver injury that provides a permissive environment for cancer development, is characterized by accumulation of extracellular matrix components mainly derived from activated hepatic stellate cells (HSCs). Axl, a receptor tyrosine kinase and its ligand Gas6, are involved in cell differentiation, immune response and carcinogenesis. Methods HSCs were obtained from WT and Axl<sup>-/-</sup> mice, treated with recombinant Gas6 protein (rGas6), Axl siRNAs or the Axl inhibitor BGB324, and analyzed by western blot and real-time PCR. Experimental fibrosis was studied in CCl<inf>4</inf>-treated WT and Axl<sup>-/-</sup> mice, and in combination with Axl inhibitor. Gas6 and Axl serum levels were measured in alcoholic liver disease (ALD) and hepatitis C virus (HCV) patients. Results In primary mouse HSCs, Gas6 and Axl levels paralleled HSC activation. rGas6 phosphorylated Axl and AKT prior to HSC phenotypic changes, while Axl siRNA silencing reduced HSC activation. Moreover, BGB324 blocked Axl/AKT phosphorylation and diminished HSC activation. In addition, Axl<sup>-/-</sup> mice displayed decreased HSC activation in vitro and liver fibrogenesis after chronic damage by CCl<inf>4</inf> administration. Similarly, BGB324 reduced collagen deposition and CCl<inf>4</inf>-induced liver fibrosis in mice. Importantly, Gas6 and Axl serum levels increased in ALD and HCV patients, inversely correlating with liver functionality. Conclusions The Gas6/Axl axis is required for full HSC activation. Gas6 and Axl serum levels increase in parallel to chronic liver disease progression. Axl targeting may be a therapeutic strategy for liver fibrosis management.
Versión del editorhttp://dx.doi.org/10.1016/j.jhep.2015.04.013
URIhttp://hdl.handle.net/10261/124600
DOI10.1016/j.jhep.2015.04.013
Identificadoresdoi: 10.1016/j.jhep.2015.04.013
issn: 1600-0641
Aparece en las colecciones: (IIBB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Barcena-JHepatology-2015-v63-p670.pdf826,92 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.